Replies to post #16416 on Synaptogenix Inc (SNPX)

[Cyosol]

I doubt there will be enough left for other indications.

Personally I'm just looking forward to getting rid of Silverman & Ryan. Especially Silverman.

[InTheTrenches]

Coach:

I'm just ready to get the merger over one way or another. If we have the extra cash then move on to other indications.

Running a few other exploratory Phase 1 trials is an excellent way to delve into other indications, and it is worth the cost! Just look at TRIL, who was trading at .30 about 9 months ago, and are now at $13 or so. TRIL is STILL only in Phase 1 dose escalation trials (with good monotherapy results).

For NTRP, a small phase 1 trial should cost >$1M for each indication (~15 patients, no dose escalation, no placebo arm).

Seems like it would be money well-spent, choosing 3-4 indications.

-------

Coach: On another note, have you calculated when we can expect a readout from NTRP's current AD trial? Thanks.